Studies of intravitreal carries for sustained released of ophthalmic drugs by P(NIPAAm-co-AAc)

碩士 === 長庚大學 === 生化與生醫工程研究所 === 96 === Abstract Age-related macular degeneration (AMD) is one of the angiogenesis ocular diseases. Numerous methods have been developed to prevent the patients losing of vision. In clinical, one of the treating methods is intravitreal administration of anti-VEGF (vascu...

Full description

Bibliographic Details
Main Authors: Yung Ann Chen, 陳永安
Other Authors: S. W. Tsai
Format: Others
Published: 2008
Online Access:http://ndltd.ncl.edu.tw/handle/45591515914139796006
Description
Summary:碩士 === 長庚大學 === 生化與生醫工程研究所 === 96 === Abstract Age-related macular degeneration (AMD) is one of the angiogenesis ocular diseases. Numerous methods have been developed to prevent the patients losing of vision. In clinical, one of the treating methods is intravitreal administration of anti-VEGF (vascular endothelial growth factor) antibody, Avastin that is a full-length monoclonal antibody against the VEGF molecule. However, Avastin is hinder by the short half-life when using intravitreal injection directly. Thus, the purpose of this study is to fabrication a sustained release carrier of Avastin by P(NIPAAm-co-AAc) hydrogel and characterization. Various copolymer of P(NIPAAm-co-AAc) were prepared by polymerization with various molar ratio of N-isopropylacrylamide (NIPAAm) to acrylic acid (AAc). Experimental results inducated all of these hydrogels could completely gelation less than 3 minutes. Mixture of copolymer and various molecular weight proteins to investigate the release profiles. From the in vitro studies, the P(NIPAAm) hydrogel was found to display significant burst release compared P(NIPAAm-co-AAc) regardless proteins used. And the release amount of bovine serum albumin, γ-globulin and Avastin could reach more than 75% in both of P(NIPAAm) and P(NIPAAm-co-AAc) hydrogels within 1200 minutes. The hydrogel system does not alter the administration method of Avastin, but also could elongation the half-time of Avastin, and may offer a mean of delivering other therapeutic agents in the future.